Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective comparison of telitacicept versus belimumab in lupus nephritis
ChiCTR2500108674Phase 4Not yet recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of telitacicept and belimumab in lupus nephritis (LN) (2 arms), sponsored by Shandong Provincial Qianfoshan Hospital. Primary endpoint: Major renal efficacy response rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
telitaciceptbelimumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on ChiCTR2500108674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108674.